12 Oversold NASDAQ Stocks to Buy Now
On July 14, Max Kettner, chief multi-asset strategist at HSBC, appeared on CNBC to talk about the global markets amid trade tensions.
Immunovant Inc. (IMVT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Deep Track Capital David Kroin | 9,500,000 | $152,000,000 | 4.87% | |
| 2. | Baker Bros. Advisors Julian Baker And Felix Baker | 5,457,881 | $87,326,096 | 0.85% | |
| 3. | Armistice Capital Steven Boyd | 5,200,000 | $83,200,000 | +16% | 1.44% |
| 4. | Point72 Asset Management Steve Cohen | 3,336,250 | $53,379,994 | +317% | 0.1% |
| 5. | Two Seas Capital Sina Toussi | 2,252,772 | $36,044,352 | +38% | 0.61% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $20.00 | 16,845,010 | $336,900,200.00 | 96,650,341 | 2025-01-13 | Filing | |
| $38.00 | 1,526,316 | $58,000,008.00 | 79,805,331 | 2023-10-02 | Filing | |
| $6.00 | 416,667 | $2,500,002.00 | 73,805,331 | 2022-10-06 | Filing | |
| $5.60 | 15,000 | $84,000.00 | 20,000 | 2022-09-30 | Filing | |
| $5.81 | 20,000 | $116,200.00 | 393,358 | 2022-09-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $18.15 | 2,805 | $50,910.75 | 204,919 | 2025-07-23 | Filing | |
| $18.15 | 2,385 | $43,287.75 | 221,825 | 2025-07-23 | Filing | |
| $17.24 | 1,160 | $19,998.40 | 224,210 | 2025-07-09 | Filing | |
| $17.24 | 1,519 | $26,187.56 | 207,724 | 2025-07-09 | Filing | |
| $14.79 | 1,925 | $28,470.75 | 209,243 | 2025-04-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,599,195 | $297,587,112 | 0.02% | |
| 2. | 7,025,938 | $112,415,008 | 0% | |
| 3. | 5,848,285 | $93,572,560 | 0% | |
| 4. | 2,830,074 | $45,281,184 | 0% | |
| 5. | 2,626,692 | $42,027,072 | 9.47% |
News See All
LifeSci Capital Maintains a Buy on Immunovant (IMVT) With a $50 PT
Immunovant, Inc. (NASDAQ:IMVT) is one of the 13 Best Pharma Stocks to Buy According to Wall Street Analysts.
13 Best Pharma Stocks to Buy According to Wall Street Analysts
On June 24, Jared Holz, Mizuho's healthcare strategist, appeared on CNBC's 'Fast Money' to talk about competition in the obesity drug space.
Smart Money Ratings For 20 Most Undervalued Stocks
We have passed a quarter into 2025, and the U.S. economy sends mixed signals, causing investors to scramble and decode them. The U.S.
11 Stocks That Will Bounce Back According to Analysts
Major US indexes finished in the green on Wednesday, May 7, after a volatile session as investors reacted to updates from the Federal Reserve and new trade developments.
10 Best Low Cost Stocks to Buy According to Billionaires
Markets are wobbling, and panic is becoming the headline. At times when stocks are tumbling, headlines are filled with forecasts that cause anxiety for investors. But it's not new.
10 Oversold Pharma Stocks to Buy According to Analysts
On February 20, Emily Field, Head of European Pharma Research at Barclays, appeared on CNBC to discuss the dynamics of the pharmaceutical sector, the impact of US tariffs, and the performance of obesity...
12 Most Oversold Healthcare Stocks to Buy Now
Healthcare costs and spending have been rising in the US. The Centers for Medicare & Medicaid Services reported that healthcare spending in the US reached $4.9 trillion in 2023, up 7.5% from 2022.
10 Stocks Insiders Spent The Most Money On Recently
As the broader market continues to rise this year, we thought it would be interesting to highlight some stocks that have seen significant insider buying recently.
12 Stocks That Will Double in 2025
A lot is happening in the market, especially within the growth sectors.
Billionaire Hedge Funds
